X

Trial Profile

A Phase 2 Study Of Bevacizumab And Interferon-Alpha-2b In Metastatic Malignant Melanoma.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Interferon alpha-2b (Primary)
Indications Malignant melanoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

16 Mar 2016 Patients are differentiated based on dose of Interferon Alfa on different days along with change in the time frame of primary end points as per ClinicalTrials.gov record.
10 Apr 2013 Planned end date changed from 1 Sep 2002 to 1 Apr 2016 as reported by ClinicalTrials.gov.
17 Dec 2009 Planned number of patients changed from 50 to 65 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com